These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 15800664)
1. The cost-effectiveness of candesartan-based antihypertensive treatment for the prevention of nonfatal stroke: results from the Study on COgnition and Prognosis in the Elderly. Lundkvist J; Ekman M; Kartman B; Carlsson J; Jönsson L; Lithell H J Hum Hypertens; 2005 Jul; 19(7):569-76. PubMed ID: 15800664 [TBL] [Abstract][Full Text] [Related]
2. Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE). Papademetriou V; Farsang C; Elmfeldt D; Hofman A; Lithell H; Olofsson B; Skoog I; Trenkwalder P; Zanchetti A; J Am Coll Cardiol; 2004 Sep; 44(6):1175-80. PubMed ID: 15364316 [TBL] [Abstract][Full Text] [Related]
3. Candesartan cilexetil: a pharmacoeconomic review of its use in chronic heart failure and hypertension. Plosker GL; Keam SJ Pharmacoeconomics; 2006; 24(12):1249-72. PubMed ID: 17129078 [TBL] [Abstract][Full Text] [Related]
4. Resource utilization and costs in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. McMurray JJ; Andersson FL; Stewart S; Svensson K; Solal AC; Dietz R; Vanhaecke J; van Veldhuisen DJ; Ostergren J; Granger CB; Yusuf S; Pfeffer MA; Swedberg K Eur Heart J; 2006 Jun; 27(12):1447-58. PubMed ID: 16754631 [TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of losartan-based therapy in patients with hypertension and left ventricular hypertrophy: a UK-based economic evaluation of the Losartan Intervention for Endpoint reduction in hypertension (LIFE) study. McInnes G; Burke TA; Carides G J Hum Hypertens; 2006 Jan; 20(1):51-8. PubMed ID: 16357874 [TBL] [Abstract][Full Text] [Related]
6. The Study on COgnition and Prognosis in the Elderly (SCOPE)--recent analyses. Trenkwalder P J Hypertens Suppl; 2006 Mar; 24(1):S107-14. PubMed ID: 16601563 [TBL] [Abstract][Full Text] [Related]
7. An angiotensin receptor blocker reduces the risk of congestive heart failure in elderly hypertensive patients with renal insufficiency. Nakamura T; Kanno Y; Takenaka T; Suzuki H; Hypertens Res; 2005 May; 28(5):415-23. PubMed ID: 16156505 [TBL] [Abstract][Full Text] [Related]
8. Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE). Skoog I; Lithell H; Hansson L; Elmfeldt D; Hofman A; Olofsson B; Trenkwalder P; Zanchetti A; Am J Hypertens; 2005 Aug; 18(8):1052-9. PubMed ID: 16109319 [TBL] [Abstract][Full Text] [Related]
9. Comparative clinical- and cost-effectiveness of candesartan and losartan in the management of hypertension and heart failure: a systematic review, meta- and cost-utility analysis. Grosso AM; Bodalia PN; Macallister RJ; Hingorani AD; Moon JC; Scott MA Int J Clin Pract; 2011 Mar; 65(3):253-63. PubMed ID: 21284790 [TBL] [Abstract][Full Text] [Related]
10. Findings and implications of the Study on COgnition and Prognosis in the Elderly (SCOPE) - a review. Zanchetti A; Elmfeldt D Blood Press; 2006; 15(2):71-9. PubMed ID: 16754269 [TBL] [Abstract][Full Text] [Related]
11. Choice of angiotensin receptor blocker in moderate hypertension. A UK-based cost-benefit comparison of olmesartan- and candesartan-based regimens. Belsey JD J Med Econ; 2011; 14(5):553-61. PubMed ID: 21707445 [TBL] [Abstract][Full Text] [Related]
12. Health-related quality of life during treatment of elderly patients with hypertension: results from the Study on COgnition and Prognosis in the Elderly (SCOPE). Degl'Innocenti A; Elmfeldt D; Hofman A; Lithell H; Olofsson B; Skoog I; Trenkwalder P; Zanchetti A; Wiklund I J Hum Hypertens; 2004 Apr; 18(4):239-45. PubMed ID: 15037872 [TBL] [Abstract][Full Text] [Related]
13. Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE). Kasanuki H; Hagiwara N; Hosoda S; Sumiyoshi T; Honda T; Haze K; Nagashima M; Yamaguchi J; Origasa H; Urashima M; Ogawa H; Eur Heart J; 2009 May; 30(10):1203-12. PubMed ID: 19346521 [TBL] [Abstract][Full Text] [Related]
14. A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA. Palmer AJ; Valentine WJ; Chen R; Mehin N; Gabriel S; Bregman B; Rodby RA Nephrol Dial Transplant; 2008 Apr; 23(4):1216-23. PubMed ID: 18359872 [TBL] [Abstract][Full Text] [Related]
15. Long-term effects of candesartan and amlodipine on cardiovascular morbidity and mortality in Japanese high-risk hypertensive patients: the Candesartan Antihypertensive Survival Evaluation in Japan Extension Study (CASE-J Ex). Ogihara T; Ueshima K; Nakao K; Fukiyama K; Oba K; Yasuno S; Fujimoto A; Sato T; Matsuoka H; Saruta T; Hypertens Res; 2011 Dec; 34(12):1295-301. PubMed ID: 21833000 [TBL] [Abstract][Full Text] [Related]
16. Cost implications of development of diabetes in the ALPINE study. Lindholm LH; Kartman B; Carlberg B; Persson M; Svensson A; Samuelsson O J Hypertens Suppl; 2006 Mar; 24(1):S65-72. PubMed ID: 16601576 [TBL] [Abstract][Full Text] [Related]
17. Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis--a randomized study. Takahashi A; Takase H; Toriyama T; Sugiura T; Kurita Y; Ueda R; Dohi Y Nephrol Dial Transplant; 2006 Sep; 21(9):2507-12. PubMed ID: 16766543 [TBL] [Abstract][Full Text] [Related]
18. Effects of candesartan on cardiovascular outcomes in Japanese hypertensive patients. Suzuki H; Kanno Y; Hypertens Res; 2005 Apr; 28(4):307-14. PubMed ID: 16138560 [TBL] [Abstract][Full Text] [Related]